Literature DB >> 16052255

Vitreous leptin levels in retinal disease.

D Maberley1, J Z Cui, J A Matsubara.   

Abstract

BACKGROUND/AIMS: The purpose of this study was to investigate the relationship between vitreous leptin levels and retinal diseases.
METHODS: Levels of vitreous leptin were evaluated in proliferative diabetic retinopathy (PDR) and a variety of other retinopathies including: macular disease, neovascular maculopathies, primary retinal detachments, and vascular occlusive disease.
RESULTS: In patients with PDR (N=7), the average vitreous level of leptin (37.4 ng/ml) was significantly higher than that in patients with PVR (<1.0 ng/ml, P<0.05). Vitreous leptin level in patients with PVR or macular disease (N=18), with or without diabetes, was not significantly different from the control subjects who had retinal detachment only (N=7).
CONCLUSION: The results show that the leptin level in vitreous taps is elevated in PDR. We suggest that leptin plays an active role in PDR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052255     DOI: 10.1038/sj.eye.6702011

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  13 in total

1.  Plasma and vitreous fluid levels of Dickkopf-1 in patients with diabetic retinopathy.

Authors:  F Qiu; J He; Y Zhou; X Bai; G Wu; X Wang; Z Liu; Y Chen; J-X Ma; Z Liu
Journal:  Eye (Lond)       Date:  2014-01-10       Impact factor: 3.775

2.  N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

Authors:  Hetian Lei; Gisela Velez; Jing Cui; Arif Samad; David Maberley; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

3.  A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Authors:  Steven Pennock; Marc-Andre Rheaume; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2011-10-28       Impact factor: 4.307

4.  Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy.

Authors:  Makiko Katagiri; Jun Shoji; Noriko Inada; Satoshi Kato; Shigehiko Kitano; Yasuko Uchigata
Journal:  Int Ophthalmol       Date:  2017-03-15       Impact factor: 2.031

5.  Leptin activates the JAK/STAT pathway to promote angiogenesis in RF/6A cells in vitro.

Authors:  Le Zhang; Rong Li; Bing-Hui Wu; Ting-Ting Liang; Zhe Liu; Wei Ju; Yi Wang; Yu-Ting Wen; Ming-Cui Liu; Jun-Hui Du
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

6.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

7.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

8.  CFH Y402H polymorphism is associated with elevated vitreal GM-CSF and choroidal macrophages in the postmortem human eye.

Authors:  Jay Ching Chieh Wang; Sijia Cao; Aikun Wang; Eleanor To; Geoffrey Law; Jiangyuan Gao; Dean Zhang; Jing Z Cui; Joanne A Matsubara
Journal:  Mol Vis       Date:  2015-03-13       Impact factor: 2.367

9.  Duplicated leptin receptors in two species of eel bring new insights into the evolution of the leptin system in vertebrates.

Authors:  Marina Morini; Jérémy Pasquier; Ron Dirks; Guido van den Thillart; Jonna Tomkiewicz; Karine Rousseau; Sylvie Dufour; Anne-Gaëlle Lafont
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

10.  Exploring leptin antagonism in ophthalmic cell models.

Authors:  Laura Scolaro; Cristina Parrino; Roberta Coroniti; Laszlo Otvos; Eva Surmacz
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.